Kiniksa Pharmaceuticals Files 8-K on Operations
Ticker: KNSA · Form: 8-K · Filed: 2024-07-23T00:00:00.000Z
Sentiment: neutral
Topics: 8-k, financial-condition, operations
TL;DR
Kiniksa dropped an 8-K on July 23rd about their financials. Keep an eye on this.
AI Summary
On July 23, 2024, Kiniksa Pharmaceuticals International, plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.
Why It Matters
This filing indicates that Kiniksa Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for operational and financial updates, not indicating any immediate or specific risks.
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Registrant
- July 23, 2024 (date) — Date of earliest event reported
- England and Wales (jurisdiction) — State or other jurisdiction of incorporation or organization
- 001-38492 (commission_file_number) — Commission File Number
- 23 Old Bond Street, Floor 3 London , WIS 4PZ England , United Kingdom (address) — Business and Mail Address
- 781-431-9100 (phone_number) — Business Phone
FAQ
What specific financial information is being reported in this 8-K filing?
The provided excerpt states the filing concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail specific financial figures.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on July 23, 2024.
What is the company's full legal name and jurisdiction of incorporation?
The company's full legal name is Kiniksa Pharmaceuticals International, plc, and it is incorporated in England and Wales.
What is the Commission File Number for Kiniksa Pharmaceuticals International, plc?
The Commission File Number for Kiniksa Pharmaceuticals International, plc is 001-38492.
Where is Kiniksa Pharmaceuticals International, plc headquartered?
Kiniksa Pharmaceuticals International, plc is headquartered at 23 Old Bond Street, Floor 3, London, WIS 4PZ, England, United Kingdom.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-07-23 07:54:56
Key Financial Figures
- $0.000273235 — h registered Class A Ordinary Shares $0.000273235 nominal value KNSA The Nasdaq Stock
Filing Documents
- tm2419915d1_8k.htm (8-K) — 26KB
- tm2419915d1_ex99-1.htm (EX-99.1) — 80KB
- tm2419915d1_ex99-1img001.jpg (GRAPHIC) — 19KB
- 0001104659-24-081717.txt ( ) — 311KB
- knsa-20240723.xsd (EX-101.SCH) — 3KB
- knsa-20240723_lab.xml (EX-101.LAB) — 33KB
- knsa-20240723_pre.xml (EX-101.PRE) — 22KB
- tm2419915d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On July 23, 2024, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended June 30, 2024. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Q2 Earnings Press Release issued by Kiniksa Pharmaceuticals International, plc, dated July 23, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC Date: July 23, 2024 By: /s/ Madelyn Zeylikman Madelyn Zeylikman Senior Vice President, General Counsel and Secretary